Insights & Resources

If you are new to Regulatory Affairs or building structured understanding, begin with the following core topics:

• Aligning Global Regulatory Strategy Across EMEA

→ Read Article https://insightregconsultancy.com/insights-%26-resources-1/f/aligning-global-regulatory-strategy-across-emea

• What is Regulatory Affairs? A Practical Guide for Life Sciences Professionals

→ Read Article https://insightregconsultancy.com/insights-%26-resources-1/f/1-what-is-regulatory-affairs-a-practical-guide-for-life-science

• The Drug Development Lifecycle: Where Regulatory Affairs Adds Value

→ Read Article https://insightregconsultancy.com/insights-%26-resources-1/f/2-the-drug-development-lifecycle-where-regulatory-affairs-adds

• Introduction to the Common Technical Document (CTD)

→ Read Article https://insightregconsultancy.com/insights-%26-resources-1/f/3-introduction-to-the-common-technical-document-ctd

Expert perspectives on Regulatory Affairs and Regulatory Science

These articles provide expert perspectives on Regulatory Affairs and Regulatory Science, drawing on industry experience and ongoing academic study.

They focus on interpretation, strategic thinking, and the evolving role of regulatory science in modern drug development.

Featured Insight:

• Regulatory Science vs Regulatory Affairs: Balancing Evidence and Compliance in Modern Drug Development

→ Read Article https://insightregconsultancy.com/insights-%26-resources-1/f/regulatory-science-vs-regulatory-affairs

Additional Perspective Articles:

• From Paper to Platforms: How Regulatory Affairs Has Evolved Over the Last 20 Years

→ Read Article https://insightregconsultancy.com/insights-%26-resources-1/f/from-paper-to-platforms

• Is Innovation Reducing the Need for CMC? A Regulatory Perspective

→ Read Article https://insightregconsultancy.com/insights-%26-resources-1/f/is-innovation-reducing-the-need-for-cmc

• The Future of Regulatory Affairs

→ Read Article https://insightregconsultancy.com/insights-%26-resources-1/f/4-the-future-of-regulatory-affairs

• Defining the Boundaries of Gene Therapy. 

This article draws on regulatory developments and consultation processes relating to the MHRA Gene Therapy Medicinal Products (GTMP) consultation, reflecting practical regulatory considerations within the evolving gene therapy landscape.

→ Read Article https://insightregconsultancy.com/insights-%26-resources-1/f/defining-the-boundaries-of-gene-therapy